News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioProspect Limited (BPO.AX) Buys Into US Diabetes Company Astrum Therapeutics


10/19/2005 5:13:03 PM

Queensland company Bioprospect (ASX: BPO) has dipped deep into its pockets, paying US$530,000 for a third of private Seattle-based biotech Astrum Therapeutics, which is investigating compounds that arrest the destruction of insulin-secreting cells associated with type 1 diabetes.


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES